Dr. Mike Walsh, MD, PhD, MSc, is an Associate Professor of Medicine and Health Research Methods, Evidence, and Impact and Director, Clinical Nephrology Research, Division of Nephrology at McMaster University, Medical Director, Glomerulonephritis Centre of Excellence, at St. Joseph’s Healthcare Hamilton, the Provincial Medical Lead – Person Centred Care, Ontario Renal Network, Ontario Health, and Scientist at Population Health Research Institute, Hamilton, Ontario, Canada. His publications include PEXIVAS (trial of plasma exchange and glucocorticoids in ANCA associated vasculitis), TARGET (trial of phosphate targets in dialysis), RITUXVAS (trial of rituximab in ANCA associated vasculitis), Alberta Nocturnal Dialysis Trial (trial of quotidian nocturnal dialysis in kidney failure), IMPROVE (trial of MMF in ANCA associated vasculitis), VISION (observational study of myocardial injury after noncardiac surgery), and Cleveland Clinic definition of hypotension (observational study of intraoperative blood pressure). He leads research investigating both novel and repurposed treatments for patients with kidney diseases with particular interests in glomerular diseases, vasculitis, symptoms of kidney failure, and cardiovascular complications of chronic kidney disease and kidney failure.